Hylan GF-20 Viscosupplementation in the Treatment of Symptomatic Osteoarthritis of the Knee: Clinical Effect Survivorship at 5 Years
- Author:
Tarek BOUTEFNOUCHET
1
;
Guru PURANIK
;
Esther HOLMES
;
Karl M BELL
Author Information
- Publication Type:Original Article
- Keywords: Knee; Osteoarthritis; Intra-articular injections; Viscosupplementation; Hyaluronic acid; Treatment outcome; Survival
- MeSH: Arthroplasty; Follow-Up Studies; Humans; Hyaluronic Acid; Injections, Intra-Articular; Knee; Molecular Weight; Osteoarthritis; Osteoarthritis, Knee; Patient Selection; Retrospective Studies; Survival Rate; Treatment Outcome; Viscosupplementation; Viscosupplements
- From:The Journal of Korean Knee Society 2017;29(2):129-136
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Controversies remain surrounding the choice of hyaluronic acid products and patient selection. A study was conducted to report the long-term survivorship of intra-articular injection effect of high molecular weight hyaluronic preparation hylan GF-20 (Synvisc-One) for patients with symptomatic knee osteoarthritis. MATERIALS AND METHODS: A retrospective observational analysis of a single therapeutic series was carried out. The analysis was conducted to determine therapeutic effect survivorship taking arthroplasty and any other surgical interventions as endpoint results. RESULTS: Seventy-seven consecutive patients (82 knees) were followed up for five years. At one-year follow-up, 71 knees (87%) responded to treatment and only 8 knees (10%) were offered arthroplasty due to persistence of symptoms. At five-year follow-up, 41 (50%) were still considered responders. During the study period, repeat injection was given in 9 knees (11%). Arthroplasty (either total or unicompartmental) was required in 26 (31%). Kaplan-Meier survivorship analysis of therapeutic effect demonstrated 67% survival at 5 years with arthroplasty as endpoint and 58% survival at 5 years with all secondary interventions as endpoint. CONCLUSIONS: This study demonstrates a significantly longer duration of clinical benefit of hylan GF-20 injection. Present results may suggest a notion of an ideal delay therapeutic strategy for patients not ready to receive an arthroplasty. Further studies will be required to help characterise these subsets of patients.
